Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 18 and 75 years old.
• People who have been newly diagnosed with a specific type of advanced ovarian, peritoneal, or fallopian tube cancer (high-grade serous or high-grade endometrioid) at stage III or IV, with high-risk features for the cancer returning — this includes stage III where surgery did not remove all visible cancer, any stage IV diagnosis, or having fluid buildup in the abdomen at the time of diagnosis.
• People who have already had primary surgery to remove as much of the ovarian cancer as possible.
• People with a general health and activity level rated as 0, 1, or 2 on a standard medical scale (meaning able to carry out at least some daily activities, from fully active to capable of self-care) (confirm with trial site).
• People who are starting treatment within 12 weeks of their surgery.
• People expected to live for at least 3 months.
• People whose blood counts within 7 days before starting treatment meet minimum levels — specifically, haemoglobin at least 90 g/L, a type of white blood cell count (neutrophils) at least 1.5×10⁹/L, and platelets at least 100×10⁹/L.
• People whose liver and kidney function blood test results fall within acceptable ranges — including bilirubin, liver enzymes (ALT and AST), and creatinine levels meeting specified thresholds (confirm with trial site for exact values).
• People who are able to use effective contraception if there is any possibility of becoming pregnant.
• People who are willing to voluntarily agree to participate and sign a consent form.
• People who are expected to attend all required follow-up appointments and comply with the study schedule.

Who may not be able to join:

• People who have previously been treated with anti-blood-vessel-growth (anti-angiogenic) drugs such as apatinib, sorafenib, anlotinib, bevacizumab, or similar therapies.
• People who are currently pregnant or breastfeeding.
• People who are currently enrolled in another clinical trial that has not yet finished.
• People who have had a significant bleeding event (more than 30 mL of blood, or bleeding involving vomiting blood, black stools, or blood in stools) within the past 3 months, coughed up 5 mL or more of fresh blood within the past 4 weeks, or had a stroke or mini-stroke within the past 12 months.
• People with high blood pressure that is not well controlled (top number 150 mmHg or higher, or bottom number 100 mmHg or higher).
• People with certain heart conditions, including heart muscle problems, irregular heartbeat (including a specific electrical reading called QTc of 480 ms or more), or moderate-to-severe heart failure.
• People with a serious active infection that is not under control.
• People with kidney failure requiring dialysis (haemodialysis or peritoneal dialysis).
• People with a weakened immune system, including those who are HIV-positive, have another immune deficiency condition, or have had an organ transplant.
• People who have had persistently high protein levels in their urine on two separate tests, confirmed by a 24-hour urine collection showing more than 1.0 g of protein.
• People with certain mental health conditions including epilepsy, dementia, severe depression, or mania.
• People with any history of bleeding disorders of any severity, a serious bleeding event (grade 3 or above) within the past 4 weeks, or wounds, ulcers, or fractures that have not healed.
• People who have had a blood clot event — such as a stroke, mini-stroke, deep vein thrombosis, or pulmonary embolism — within the past 6 months.
• People with brain metastases (cancer that has spread to the brain) that are causing symptoms, or whose symptoms have only been controlled for less than 2 months.
• People with a history of substance abuse or psychiatric disorders (this criterion appears twice in the criteria — confirm details with trial site).
• People who have difficulty swallowing or a known problem absorbing medication.
• People with a known allergy to sorafenib, paclitaxel, or carboplatin (the study drugs).
• People with any other condition that the trial medical team considers would make participation unsuitable.

Important: Always verify eligibility with the trial site directly before applying.